*3.4. Heart Transplant Recipients*

Recently, two heart transplant recipients from China with COVID-19 have been reported: one patient with a moderately severe (stage IIB) and another with a mild (stage IIA) presentation (Table 1) [20]. The first patient was a 51-year-old man on maintenance immunosuppressive therapy with tacrolimus and mycophenolate mofetil. He initially presented with fever, chills, fatigue and poor appetite, as well as diarrhea. He had a normal oxygen saturation initially, but then his clinical condition worsened, and his saturation decreased to 75% without supplemental oxygen. This was improved after giving oxygen via a face-mask. He was treated with intravenous human gammaglobulin (10 g/day) and methylprednisolone (80 mg/day) for 5 days, while immunosuppression was stopped. The initial ground-glass opacities in the chest CT showed significant improvement after therapy, and the patient was discharged from the hospital.

The second patient was a 43-year-old man with tacrolimus and mycophenolate mofetil maintenance immunosuppression, who was admitted having suffered from fever for 2 days with fairly discrete lung lesions on his chest CT (stage IIA). His clinical situation deteriorated, and he suffered from severe fatigue and poor appetite. There were no further complications and he could be discharged from the hospital.
